Welcome to our dedicated page for ProShares Nasdaq-100 Dynamic Buffer ETF news (Ticker: QB), a resource for investors and traders seeking the latest updates and insights on ProShares Nasdaq-100 Dynamic Buffer ETF stock.
The news feed for ProShares Nasdaq-100 Dynamic Buffer ETF (QB) highlights developments related to this ProShares ETF and its Dynamic Buffer strategy. ProShares has described QB as part of a group of Dynamic Buffer ETFs built on a patent-pending methodology that combines index exposure with options to shape daily risk and return. News items connected to QB often explain how the fund is intended to capture equity gains up to a daily cap while targeting a defined range of downside protection each day.
Coverage can include ProShares announcements about the launch of QB, explanations of the Dynamic Daily Buffer Strategy, and descriptions of how the targeted buffer and upside cap adjust in response to expected market volatility. These updates help investors understand how the fund’s rules-based approach is designed to respond when volatility rises or falls, and what that may mean for the level of daily protection and participation in index gains.
Because the methodology uses both long and short options on a broad-based index with one-day expirations, ProShares communications may also address the risks of derivatives usage, potential differences between the ETF’s performance and that of its underlying index, and the circumstances under which the fund might underperform. Regulatory and risk disclosures from ProShares provide additional context on how the strategy is expected to behave over time.
Investors and researchers can use this news page to follow how ProShares presents QB’s objectives, risk considerations and role within its broader ETF lineup. Returning to this page allows readers to see the sequence of official statements and product-focused commentary related specifically to ProShares Nasdaq-100 Dynamic Buffer ETF.
Guided Therapeutics (OTC:QB) said it received an $88,000 payment from Hangzhou Dongye Medical Technology (HDMT) on Dec 11, 2025. $80,000 of the payment is the third installment of a $700,000 purchase order received earlier in 2025; the remaining $8,000 is a new order for LuViva components.
The company will ship four LuViva devices and components this month, bringing total devices shipped to seven of 35 due over the next several months. HDMT is the exclusive gynecology products provider for 42 hospitals in Hangzhou, which perform about two million cervical cancer screenings annually. The purchase order was complemented by a new $200,000 initial purchase agreement with Yuanshuo Medical Instruments Corporation (YMIC) in Jiangsu province.
Guided Therapeutics (OTC:QB GTHP), manufacturer of the LuViva Advanced Cervical Scan, has received a $70,000 payment from Hangzhou Dongye Medical Technology Company (HDMT), its Chinese distribution partner. This marks the second of nine scheduled payments totaling $700,000 for LuViva components and services.
The payment triggers the shipment of three component sets and manufacturing of four additional sets. Upon completion, HDMT will make the next payment of $80,000. HDMT serves as the exclusive gynecology products provider for 42 hospitals in Hangzhou City, conducting approximately 2 million annual cervical cancer screenings.
Guided Therapeutics (OTC:QB GTHP) has completed patient enrollment in its FDA clinical trial for the LuViva Advanced Cervical Scan, a non-invasive cervical cancer detection device. The study successfully enrolled approximately 430 patients across four clinical sites, meeting minimum quota requirements.
The company is now transitioning to data analysis, which includes external review of biopsy samples, case report form evaluation, and statistical analysis. No adverse events were reported during the trial, supporting LuViva's FDA designation as a non-significant risk device. The clinical report is expected to be filed with the FDA later in 2025.
Guided Therapeutics (OTC:QB GTHP), manufacturer of the LuViva Advanced Cervical Scan, has initiated its first shipment to Hangzhou Dongye Medical Technology Company (HDMT) on June 27, 2025. This shipment will generate $117,462 in sales revenue for Q2 2025.
The company has also manufactured and tested three devices from a separate $700,000 purchase order with HDMT, triggering a $70,000 payment expected in July 2025. HDMT serves as the exclusive gynecology products provider for 42 hospitals in Hangzhou City, conducting approximately two million cervical cancer screenings annually.
ProShares has launched three innovative Dynamic Buffer ETFs tracking major U.S. indices: S&P 500 (FB), Nasdaq-100 (QB), and Russell 2000 (RB). These groundbreaking ETFs feature a patent-pending methodology that allows investors to participate in market gains up to a cap while providing dynamic downside protection of 1-5% on daily losses.
The unique feature is their automatic adjustment mechanism - as market volatility increases, both the buffer protection and upside cap increase proportionally. Unlike conventional buffer ETFs that require specific holding periods, these new products offer more flexible protection without timing restrictions. The launch comes as Buffer ETFs have accumulated $65 billion in assets under management.
Manhattan Scientifics Inc. (OTC: QB) holds over 50 million shares of Imagion Biosystems (IBX.AX), focused on developing advanced non-radioactive cancer imaging technology. A televised interview with Imagion's CEO, Bob Proulx, is highlighted, discussing their innovative diagnostic solutions aimed at early cancer detection. The press release emphasizes the partnership and technology transfer efforts with Los Alamos and Sandia National Laboratories in New Mexico. The company warns that investments are high risk, with future results uncertain, stressing forward-looking statements are not guarantees of performance.
FAQ
What is the current stock price of ProShares Nasdaq-100 Dynamic Buffer ETF (QB)?
